Literature DB >> 10354961

Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women.

Y Lin1, G D Anderson, E Kantor, L M Ojemann, A J Wilensky.   

Abstract

The urinary ratio of 6-beta-hydroxycortisol/cortisol has been used as a noninvasive probe for human cytochrome P450 3A4 isoforms (CYP3A4). Ethnic-related differences in the ratio have not been evaluated. The aim of this study was to determine if there are differences in the ratio between Asian and Caucasian women over a menstrual cycle. First-morning urine samples were collected every other day starting from the second day of menstruation for a complete menstrual cycle from 15 Asians and 16 Caucasian women who were 18 to 40 years old, healthy, nonsmoking, and alcohol and drug free, including oral contraceptives. Urine concentrations of 6-beta-hydroxycortisol and cortisol were measured by high-pressure liquid chromatography (HPLC). For statistical analysis, three phases of the menstrual cycle were evaluated: menstruation (days 1-4), follicular or postmenstruation (days 6-10), and the luteal phase (days 21-24) based on the average menstrual cycle (28 days). Statistical analysis was performed by an independent sample t-test using the Bonferroni correction for repeated measures. Large intersubject and intrasubject variations of the 6-beta-hydroxycortisol/cortisol ratios were observed during the menstrual cycles in both ethnic groups. Asian women had a statistically significant lower ratio than Caucasian women did for all three phases of the menstrual cycle: 2.2 +/- 1.1 versus 5.1 +/- 3.5, 2.1 +/- 1.1 versus 6.0 +/- 4.9, and 2.8 +/- 1.6 versus 5.6 +/- 3.0 for the menstruation, follicular, and luteal phases, respectively. The two- to threefold lower 6-beta-hydroxycortisol/cortisol ratios in Asian women suggest that Asian women may have a lower CYP3A activity compared with Caucasian women. Differences in ethnicity may mask potential gender-related effects if ethnic background is not evaluated as a contributing factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354961     DOI: 10.1177/00912709922008182

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Authors:  Kwee Poo Yeo; Stephen L Lowe; Ming Tung Lim; James R Voelker; Jennifer L Burkey; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

2.  Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.

Authors:  Sandra M Swain; Young-Hyuck Im; Seock-Ah Im; Valorie Chan; David Miles; Adam Knott; Emma Clark; Graham Ross; José Baselga
Journal:  Oncologist       Date:  2014-05-28

3.  Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.

Authors:  Qian Li; Yun Ai Su; Yi Liu; Jing Xu Chen; Yun Long Tan; Fu De Yang; Tian Mei Si
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 4.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

5.  Single- and Multiple-Dose Milnacipran Pharmacokinetics in Healthy Han Chinese Volunteers.

Authors:  Can-Jun Ruan; An-Ning Li; Fang Dong; Yi-Min Zhai; Wen-Biao Li; Chuan-Yue Wang; Jose de Leon
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

6.  Sex-dependent modulation of treatment response.

Authors:  David R Rubinow; Molly Moore
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

7.  Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.

Authors:  Binghe Xu; Xichun Hu; Hong Zheng; Xiaojia Wang; Qingyuan Zhang; Shude Cui; Donggeng Liu; Ning Liao; Rongcheng Luo; Qiang Sun; Shiying Yu
Journal:  Oncotarget       Date:  2016-08-02

8.  Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Authors:  Helena Bergström; Anna Lindahl; Anna Warnqvist; Ulf Diczfalusy; Lena Ekström; Linda Björkhem-Bergman
Journal:  Pharmacol Res Perspect       Date:  2021-12

9.  Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.

Authors:  Ehab S Eldesoky; Sherif I Kamel; Ahlam M Farghaly; Madiha Y Bakheet; Mohsen A Hedaya; Jean-Pascal Siest
Journal:  Biomark Insights       Date:  2007-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.